Abstract
Multicomponent reactions (MCRs) are a very important class of reactions that are considerably useful in the quest for new medicines and, within this category, the Ugi-MCR holds a special place. In part 2 of this series (the first was previously published) we discuss advances in the catalytic 3- and 4-component Ugi reactions (U-3-CR and U-4-CR, respectively) as regards to nanocatalysis, biocatalysis, asymmetric catalysis with organocatalysts, as well as continuous manufacturing methods such as, continuous-flow processes. Again, in this review there is a strong focus on green and sustainable versions of this important reaction. To conclude this report, the operation and implications (both presently and in the future) of this versatile and enabling reaction in the pharmaceutical industry are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 18-21 |
| Number of pages | 4 |
| Journal | Chimica Oggi |
| Volume | 37 |
| Issue number | 4 |
| Publication status | Published - 2019 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 9 Industry, Innovation, and Infrastructure
Keywords
- Biocatalysis
- Chiral phosphoric acid organocatalysts
- Continuous flow
- Enantioselectivity
- Ugi reaction
Fingerprint
Dive into the research topics of 'Catalytic Ugi reactions: Current advances, future challenges - Part 2'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver